Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC)
2004
7090 Background: We previously reported the preliminary activity and tolerability of the combination of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) and docetaxel in patients wit...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
6
Citations
NaN
KQI